Intellectual property strategy for regenerative medicine: is it time to 'regenerate'?

Pharm Pat Anal. 2014 Sep;3(5):475-9. doi: 10.4155/ppa.14.40.
No abstract available

Keywords: Mayo; cellular medicine; data/market exclusivity; induced pluripotent stem cell (iPSC); intellectual property; market approval; myriad; natural products; ordre public (public order); patent; patent eligibility; priority; regenerative medicine; stem cell.

MeSH terms

  • Biomedical Research / legislation & jurisprudence*
  • Europe
  • Government Regulation
  • Intellectual Property*
  • Patents as Topic
  • Regenerative Medicine* / legislation & jurisprudence
  • Regenerative Medicine* / organization & administration
  • United States